Fulcrum Therapeutics, Inc.

NasdaqGM:FULC Rapporto sulle azioni

Cap. di mercato: US$582.8m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Fulcrum Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Fulcrum Therapeutics ha un patrimonio netto totale di $273.8M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $294.3M e $20.5M.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessin/a
ContantiUS$273.78m
Patrimonio nettoUS$273.79m
Totale passivitàUS$20.47m
Totale attivitàUS$294.26m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Aug 11

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Jul 11

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Jul 05

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Jun 27

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

May 10
These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Apr 09
Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Dec 09
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point

Sep 03

Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

Aug 12
Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Aug 11
News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $280.3M ) di FULC superano le sue passività a breve termine ( $12.7M ).

Passività a lungo termine: Le attività a breve termine di FULC ( $280.3M ) superano le sue passività a lungo termine ( $7.8M ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: FULC è esente da debiti.

Riduzione del debito: FULC non ha avuto debiti negli ultimi 5 anni.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: FULC ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: Dati insufficienti per determinare se FULC ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.


Scoprire le aziende sane